Overview

STA-5326 in Crohn's Disease Patients

Status:
Completed

Trial end date:
2004-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Synta Pharmaceuticals Corp.